(Adnkronos) - Sono circa 120mila le persone colpite da ictus ogni anno in Italia e, di queste circa un terzo sviluppano disturbi neurologici come la spasticità, una condizione invalidante che comporta difficoltà nei movimenti, con contrazioni muscolari che rendono difficili e dolorosi anche semplici gesti quotidiani. Con infitrazioni di tossina botulinica possibile migliore di molto tale condizione senza effetti collaterali
Category
🗞
NewsTranscript
00:00There are about 120,000 people affected by ictus every year in Italy and of these about 45,000
00:11develop neurological disorders such as spasticity, an invalidating condition that causes
00:16difficulty in movements with muscle contractions that make even simple daily gestures difficult and painful
00:22. Spasticity occurs in about 19% of cases every three months and up to 38%
00:29a year from the acute episode, yet today only 18% of people who overcome the acute phase
00:35receive a spasticity diagnosis and only 5,000 benefit from the correct treatment.
00:42More than half of the patients interviewed, equal to 57% then, have not been preemptively informed
00:49of the possibility that spasticity will arise after ictus, it is read in the report, and only a
00:54quarter declare themselves well informed about this condition that compromises the performance of
01:00simple daily activities with a negative impact on the quality of life of patients and their
01:05families. Information and tempestuousness of intervention are therefore the main needs
01:09emerged from the investigation conducted by Elma Research, a market research institute specialized
01:15in the health sector and promoted by Ipsen, a biopharmaceutical company committed for over
01:2030 years in neurosciences. The research was carried out thanks to the participation of a
01:26champion of 60 people with post-ictus spasticity and presented through a video testimony
01:32on the occasion of the world ictus day. Ipsen has always been committed in the field of
01:37neurosciences, as well as oncology and rare diseases, but in neurosciences specifically
01:43we are working hard in an area of response to the needs of patients and in particular
01:49in the post-ictus phases, thanks to our research and development and the investments we are making
01:55precisely to develop new and important therapeutic solutions in order to improve
02:01the quality of life of people who encounter ictus in their lives and who develop
02:07spasticity later. In addition, it is very important for us to continue working in partnership
02:15with patient associations, with scientific societies and with institutions
02:20in order to guarantee a path that is the most adequate and most appropriate,
02:24also multidisciplinary, in order to be able to allow all patients to continue their
02:30life as a normal life and with another degree of quality. An important element then for Ipsen
02:37is also the listening of people who live in everyday life, post-ictus spasticity and
02:42who takes care of them, as in the case of the members of the Alice Italia ODD federation,
02:47of which Andrea Vigniello is president. The management of the ictus in the right times, which
02:53are those precious to save neurons in our brain, therefore in the right units,
03:00then the whole process of rehabilitation, then there is a problem, going home after this
03:06path of rehabilitation with the right information. For example, this crucial theme of spasticity
03:13is one of those information that, since it is an effect that can also come weeks,
03:19even months after ictus, often patients, even those who turn to our association,
03:28were not ready to understand that these spasms, that these contractures,
03:35particularly invalidating, must be managed. And how can this problem be treated today,
03:41so invalidating? The management of spasticity involves the intervention of a real
03:47multidisciplinary team. Certainly, there are numerous approaches available, both pharmacological
03:56and neuro-rehabilitative. Both of these approaches must be started early,
04:02recognizing tempestually patients who go against an increase in muscle tone,
04:08in other words, to the emergence of spasticity. The medical intervention must be tempestuous
04:15and can be based on specific pharmacological therapies. In particular, among medical therapies,
04:22it is very important to remember botulinum toxin. Local infiltrations of botulinum toxin
04:28are an effective and safe treatment of spasticity, as, through these treatments,
04:34we are able to controllably weaken the muscles that present this abnormal activity
04:41that is at the basis of spasticity, allowing the residual strength of the patient to act
04:48those possible movements, if possible, and no longer hindered by this resistance
04:55that spasticity offers to movements.